Abattis Signs LOI With Kanabé to Provide a Full Suite of Downstream Cannabis Solutions to Their Premium Health and Wellness Products

Ryan Allway

March 8th, 2018

News, Top News

VANCOUVER, British Columbia, March 8, 2018 /PRNewswire/ — Abattis Bioceuticals Corp. (the “Company” or “Abattis“) (CSE: ATT) (OTC: ATTBF) is pleased to announce it has signed a letter of intent (the “LOI“) with Kanabé Corp. (“Kanabé“) to provide Kanabé with cannabinoids as well as formulation, manufacturing, analytical and regulatory services to support the development and commercialization of Kanabé’s products. Kanabé is a Calgary-based manufacturer of various health and wellness products, including topicals, sublingual oils and other skin-care products. Pursuant to the LOI, Abattis and Kanabé have agreed to negotiate in good faith the terms of a definitive research services agreement respecting the terms of their partnership.

“We hope our partnership with Kanabé will enable it to scale its manufacturing capacity, allowing it to enter new retail distribution channels, including storefronts throughout Canada and online stores. Kanabé’s product line will focus on the adult-use market and will be based on Abattis’s downstream cannabis solutions, resulting in a premium product and unparalleled customer experience”, stated Rob Abenante, President and CEO of Abattis. “This is the latest example of our fully-integrated suite of services supporting manufacturers of cannabis- and hemp-infused products from formulation to distribution”, added Mr. Abenante.

“Kanabé believes this partnership will enhance our formulations, with access to Abattis’s full range of services and industry leading technologies, and result in premium quality products. Concurrently with our work with Abattis, we are working to secure distribution agreements for our line of health and wellness products with major retail chains, one of which has 100+ locations throughout various provinces. We are also poised and well situated to provide our products in distribution channels overseen by provincial commissions”, stated Daniel Laferriere, CEO and founder of Kanabé Corp.

“Innovation and compliance are key drivers of our strategy to support the nascent legal market for cannabis and hemp products. For example, Kanabé’s line of high-end health and wellness products could be an ideal use case for our nanotechnology-based delivery platform currently in development,” added Dr. David Galvez, Senior Science Advisor at Abattis.

About Abattis Bioceuticals Corp.

Abattis is a life sciences and biotechnology company which aggregates, integrates, and invests in cannabis technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets. The Company is also seeking to acquire exclusive intellectual property rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company follows strict standard operating protocols, and adheres to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company’s website at: www.abattis.com

ON BEHALF OF THE BOARD OF

ABATTIS BIOCEUTICALS CORP.,

“Rob Abenante“

Robert Abenante, President & CEO

For more information, please visit the Company’s website at: www.abattis.com or www.northernvinelabs.com

This press release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “intends”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Forward-looking statements in this press release include statements regarding: the parties’ plans to enter into a definitive research services agreement; Abattis’s provision of cannabinoids and services to Kanabé; the expected benefits to both Abattis and Kanabé of the parties’ partnership; Kanabé’s plans to provide its products in distribution channels overseen by provincial commissions; Kanabé’s line of high-end health and wellness products being an ideal use case for Abattis’s nanotechnology-based delivery platform currently in development. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties, including: that a definitive research services agreement respecting the partnership will not be entered into or that the partnership will not be formed; that Abattis will not provide cannabinoids and services to Kanabé as expected; that the partnership between Abattis and Kanabé will not benefit either party as expected or at all; that Kanabé will not be able to provide its products in distribution channels overseen by provincial commissions; that Kanabé’s line of high-end health and wellness products may not be an ideal use case for Abattis’s nanotechnology-based delivery platform currently in development; that the Company will not be able to execute its proposed business plan in the time required or at all due to regulatory, financial or other issues; that the Company’s competitors may develop competing technologies; changes in regulatory requirements; and other factors beyond the Company’s control. Additional risk factors are included in the Company’s Management’s Discussion and Analysis, available under the Company’s profile on www.sedar.com. The forward-looking statements are made as at the date hereof and the Company disclaims any intent or obligation to publicly update any forward-looking statements, where because of new information, future events or results, or otherwise, except as required by applicable securities laws.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAS REVIEWED OR ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

For inquiries, please contact the Company at (604) 674-8232 or at news@abattis.com.

View original content:http://www.prnewswire.com/news-releases/abattis-signs-loi-with-kanabe-to-provide-a-full-suite-of-downstream-cannabis-solutions-to-their-premium-health-and-wellness-products-300610657.html

SOURCE Abattis Bioceuticals Corp

Source: PR Newswire (March 8, 2018 – 7:43 AM EST)

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Search CannabisFN

Press Coverage

Psychedelics Index

Visit the CFN Video Library

Join Our Facebook Page

Top Videos

Matt Hawkins of Cresco Capital Partners

Matt Hawkins is the founder and managing principal of Cresco Capital Partners, LLC (“Cresco”), a private equity firm focused specifically on investing in the legalized cannabis industry. Since its inception in the summer of 2015, Cresco has made 14 investments out of its first fund and is currently raising this fund, Fund II. Prior to the […]

Matthew Nordgren of ARCADIAN Fund

Matthew Nordgren is an ambitious executive, dedicated philanthropist, and accomplished athlete who brings a unique passion to creating strategic alliances. He has breadth and depth of experience in finance, corporate development, and capital sourcing, as well as in building highly motivated teams of skilled professionals. In 2005, Mr. Nordgren received his education at the University […]

Ovation Science Inc.

Ovation Science Inc. is a research and development company that develops topical and transdermal consumer products including its CBD/THC cannabis formulations including ARLO CBD Beauty and InVibe® MD (“health & wellness” line), and secondly, its unique DermSafe® hand sanitizer; all made with its patented Invisicare® skin delivery technology.

Mojave Jane Brands Inc.

Mojave Jane Brands Inc. is a Canadian-based cannabis sector brand and distribution company emerging as a true vertical integrator in California’s legal cannabis space serving recreational and wellness markets. The Company’s U.S. holdings are comprised of assets set up as a vertical stack including cultivation to scale, branding, packaging, manufacturing & processing, as well as, […]

Network Partners

Follow Us on Social Media

Facebook

Twitter

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.